贸易争端下中美医药贸易竞争性与互补性分析【摘要】 在 2018 年，美国对中国及其他国家实施了美国进出口商品加征关税的政策，面对美国的关税施压，中国及时给予回应，由此中美双方开始了一场以关税为中心的漫长贸易战。美国和中国作为全球前二大规模的药品市场，自我国加入世界贸易组织以来，随着全球医药贸易逐渐一体化，我国医药行业发展迅速，但受此次中美贸易争端影响，医药贸易必然受到影响。因此，本文针对中美贸易争端背景下研究中美医药贸易发展状况，并着重讨论中美医药贸易的竞争性和互补性，作出实证分析。本次研究基于 2014-2018 年贸易数据，选取中国人民共和国海关总署、世界贸易组织数据库以及联合国贸易数据库中的有关医药数据，运用产品相似性指数、显示性比较优势指数、贸易结合度指数以及贸易互补性指数，分析出中国出口到美国的优劣势医药产品，最后根据实证分析结果提出针对性建议，从政府和企业的角度提出中美医药贸易发展策略，包括医药行业的发展方针、鼓励技术创新和行业投资力度、强化中美医药企业合作、提升产品质量加强监管等合理性建议。【关键词】中美贸易争端；中美医药贸易；竞争性；互补性Competitiveness and Complementarity of Sino-US Pharmaceutical Trade under Trade Disputes[Abstract] In 2018, the United States implemented the policy of imposing tariffs on U.S. imports and exports from China and other countries. In the face of U.S. tariff pressure, China responded in a timely manner. As a result, China and the United States began a long, tariff-centric long trade war. In terms of the size of the top three pharmaceutical markets, the United States is the largest pharmaceutical market in the world. China, as the second largest pharmaceutical market in the world, has been developing rapidly since the country joined the World Trade Organization. Affected by the Sino-US trade dispute, the pharmaceutical trade is bound to be affected. Therefore, this article aims to study the development of Sino-US pharmaceutical trade in the context of Sino-US trade disputes, and focuses on di...
